- Home
- BHFAM vs WGSWW Comparison
BHFAM vs WGSWW Comparison
Compare BHFAM & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BHFAM | WGSWW |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | 1400 | 1000 |
| Industry | Life Insurance | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BHFAM | WGSWW |
|---|---|---|
| Price | $11.43 | $0.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 36.6K |
| Earning Date | N/A | 02-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $305,450,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.79 |
| 52 Week Low | N/A | $0.17 |
| 52 Week High | N/A | $0.21 |
Technical Indicators
Market Signals| Indicator | BHFAM | WGSWW |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 37.82 |
| Support Level | $10.86 | $0.03 |
| Resistance Level | $11.50 | $0.05 |
| Average True Range (ATR) | 0.20 | 0.01 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 84.37 | 19.89 |
Price Performance
Historical ComparisonAbout BHFAM Brighthouse Financial Inc.
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.